Research programme: targeted MRI contrast agents - Starpharma

Drug Profile

Research programme: targeted MRI contrast agents - Starpharma

Latest Information Update: 13 Apr 2011

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Starpharma
  • Developer Baker IDI; National Cancer Institute (USA); Starpharma
  • Class Contrast media
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cardiovascular disorders; Ovarian cancer

Most Recent Events

  • 29 Feb 2008 Early research in Cardiovascular disorders in Australia (Parenteral)
  • 29 Feb 2008 Early research in Ovarian cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top